search
Back to results

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Placebo
BI 1356 dose 3 once daily
BI 1356 dose 2 once daily
BI 1356 dose 1 once daily
Metformin
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

21 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria: Male and female patients with a diagnosis of Type 2 diabetes treated only with diet and exercise (drug naïve) or with one or two oral hypoglycemic agents (as single treatment or in combination) other than rosiglitazone or pioglitazone -treatment. Antidiabetic therapy has to be stable for at least 10 weeks prior to screening. Diagnosis of Type 2 diabetes with duration of at least 3 months Glycosylated haemoglobin A1 (HbA1c) of: 7.5-10.0% at screening for drug naïve patients (no wash-out needed) 7.0-9.0% at screening for patients treated with only one oral antidiabetic agent (wash-out required) 6.5-8.0% at screening for patients treated with two oral antidiabetic agents (wash-out required) HbA1c of 7.5%-10.0% at Visit 3 (beginning of the 2-week placebo run-in period). Age >=21 and <=75 years. BMI (Body Mass Index) >=25.0 and <=40 kg/m2. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation Exclusion criteria: Clinically relevant cardiovascular disease (e.g., myocardial infarction, stroke or transient ischemic attack within six months before enrollment) Impaired hepatic function defined by serum levels of either alanine aminotransferase, aspartate aminotransferase or alkaline phosphatase above 3-fold upper limit of normal Renal insufficiency or impaired renal function defined by serum creatinine above upper limit of normal at screening Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or clinically relevant neurologic disorders (including cerebrovascular but with the exception of polyneuropathy) that would interfere with participation in the trial Chronic or clinically relevant acute infections (e.g., Human immunodeficiency virus, Hepatitis) History of relevant allergy/hypersensitivity that would interfere with trial participation (including allergy to investigational product or its excipients) Treatment with rosiglitazone or pioglitazone within 6 months prior to screening Treatment with insulin within 3 months prior to screening Alcohol or drug abuse within the last 3 months that would interfere with trial participation) Participation in another trial with an investigational drug within two months prior to administration or during the trial Fasting plasma glucose >240 mg/dl (= 13.3 mmol/L) at Visit 2, 3 or 4 any visit and confirmed by a second measurement (not on the same day) Pre-menopausal women (last menstruation <=1 year prior to signing informed consent) who: are not surgically sterile, or are nursing or pregnant; or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra-uterine devices, oral, implantable or injectable contraceptives and vasectomised partner. No exception will be made. Intolerance of metformin

Sites / Locations

  • 1218.5.10020 Boehringer Ingelheim Investigational Site
  • 1218.5.10001 Boehringer Ingelheim Investigational Site
  • 1218.5.10007 Boehringer Ingelheim Investigational Site
  • 1218.5.10041 Boehringer Ingelheim Investigational Site
  • 1218.5.10018 Boehringer Ingelheim Investigational Site
  • 1218.5.10016 Boehringer Ingelheim Investigational Site
  • 1218.5.10003 Boehringer Ingelheim Investigational Site
  • 1218.5.10011 Boehringer Ingelheim Investigational Site
  • 1218.5.10012 Boehringer Ingelheim Investigational Site
  • 1218.5.10017 Boehringer Ingelheim Investigational Site
  • 1218.5.10008 Boehringer Ingelheim Investigational Site
  • 1218.5.10024 Boehringer Ingelheim Investigational Site
  • 1218.5.10039 Boehringer Ingelheim Investigational Site
  • 1218.5.10032 Boehringer Ingelheim Investigational Site
  • 1218.5.10025 Boehringer Ingelheim Investigational Site
  • 1218.5.10034 Boehringer Ingelheim Investigational Site
  • 1218.5.10009 Boehringer Ingelheim Investigational Site
  • 1218.5.10042 Boehringer Ingelheim Investigational Site
  • 1218.5.10029 Boehringer Ingelheim Investigational Site
  • 1218.5.10004 Boehringer Ingelheim Investigational Site
  • 1218.5.10026 Boehringer Ingelheim Investigational Site
  • 1218.5.10035 Boehringer Ingelheim Investigational Site
  • 1218.5.10023 Boehringer Ingelheim Investigational Site
  • 1218.5.10030 Boehringer Ingelheim Investigational Site
  • 1218.5.10044 Boehringer Ingelheim Investigational Site
  • 1218.5.10033 Boehringer Ingelheim Investigational Site
  • 1218.5.10038 Boehringer Ingelheim Investigational Site
  • 1218.5.10006 Boehringer Ingelheim Investigational Site
  • 1218.5.10040 Boehringer Ingelheim Investigational Site
  • 1218.5.10036 Boehringer Ingelheim Investigational Site
  • 1218.5.10021 Boehringer Ingelheim Investigational Site
  • 1218.5.10027 Boehringer Ingelheim Investigational Site
  • 1218.5.10022 Boehringer Ingelheim Investigational Site
  • 1218.5.10014 Boehringer Ingelheim Investigational Site
  • 1218.5.61001 Boehringer Ingelheim Investigational Site
  • 1218.5.61005 Boehringer Ingelheim Investigational Site
  • 1218.5.61006 Boehringer Ingelheim Investigational Site
  • 1218.5.61007 Boehringer Ingelheim Investigational Site
  • 1218.5.61004 Boehringer Ingelheim Investigational Site
  • 1218.5.61002 Boehringer Ingelheim Investigational Site
  • 1218.5.11011 Boehringer Ingelheim Investigational Site
  • 1218.5.11016 Boehringer Ingelheim Investigational Site
  • 1218.5.11003 Boehringer Ingelheim Investigational Site
  • 1218.5.11004 Boehringer Ingelheim Investigational Site
  • 1218.5.11013 Boehringer Ingelheim Investigational Site
  • 1218.5.11015 Boehringer Ingelheim Investigational Site
  • 1218.5.11005 Boehringer Ingelheim Investigational Site
  • 1218.5.11014 Boehringer Ingelheim Investigational Site
  • 1218.5.11010 Boehringer Ingelheim Investigational Site
  • 1218.5.11009 Boehringer Ingelheim Investigational Site
  • 1218.5.11012 Boehringer Ingelheim Investigational Site
  • 1218.5.11002 Boehringer Ingelheim Investigational Site
  • 1218.5.11006 Boehringer Ingelheim Investigational Site
  • 1218.5.11017 Boehringer Ingelheim Investigational Site
  • 1218.5.11018 Boehringer Ingelheim Investigational Site
  • 1218.5.42002 Boehringer Ingelheim Investigational Site
  • 1218.5.42003 Boehringer Ingelheim Investigational Site
  • 1218.5.42005 Boehringer Ingelheim Investigational Site
  • 1218.5.42004 Boehringer Ingelheim Investigational Site
  • 1218.5.42001 Boehringer Ingelheim Investigational Site
  • 1218.5.70001 Boehringer Ingelheim Investigational Site
  • 1218.5.70002 Boehringer Ingelheim Investigational Site
  • 1218.5.70003 Boehringer Ingelheim Investigational Site
  • 1218.5.70004 Boehringer Ingelheim Investigational Site
  • 1218.5.70005 Boehringer Ingelheim Investigational Site
  • 1218.5.38005 Boehringer Ingelheim Investigational Site
  • 1218.5.38001 Boehringer Ingelheim Investigational Site
  • 1218.5.38002 Boehringer Ingelheim Investigational Site
  • 1218.5.38003 Boehringer Ingelheim Investigational Site
  • 1218.5.38004 Boehringer Ingelheim Investigational Site
  • 1218.5.38006 Boehringer Ingelheim Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Placebo Comparator

Experimental

Experimental

Experimental

Active Comparator

Arm Label

Placebo

BI 1356 0.5 mg

BI 1356 2.5 mg

BI 1356 5.0 mg

Metformin

Arm Description

Placebo tablets matching BI 1356

BI 1356 dose 1 once daily

BI 1356 dose 2 once daily

BI 1356 dose 3 once daily

Metformin

Outcomes

Primary Outcome Measures

Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 12
The change from baseline reflects the Week 12 HbA1c minus the Week 0 HbA1c. Means are adjusted for baseline HbA1c.

Secondary Outcome Measures

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12
Change from baseline reflects the Week 12 FPG minus the Week 0 FPG. Means are adjusted for baseline FPG.
Percentage of Patients With Absolute Efficacy Response (HbA1c <= 7.0%) at 12 Weeks
An absolute efficacy response is defined as HbA1c <= 7.0% at 12 weeks. A non-response is defined as HbA1c > 7.0% at 12 weeks.

Full Information

First Posted
May 18, 2006
Last Updated
February 15, 2014
Sponsor
Boehringer Ingelheim
search

1. Study Identification

Unique Protocol Identification Number
NCT00328172
Brief Title
Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients
Official Title
A Randomized, Double-blind, Placebo-controlled, Five Parallel Group Study Investigating the Efficacy and Safety of BI 1356 BS (0.5 mg, 2.5 mg and 5.0 mg Administered Orally Once Daily) Over 12 Weeks in Drug Naive and Treated Patients With Type 2 Diabetes With Insufficient Glycemic Control (Study Includes an Open-label Metformin Treatment Arm)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2014
Overall Recruitment Status
Completed
Study Start Date
May 2006 (undefined)
Primary Completion Date
August 2007 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Boehringer Ingelheim

4. Oversight

5. Study Description

Brief Summary
The objective of the current study is to investigate the efficacy, safety and tolerability of several doses of BI 1356 BS (0.5, 2.5 and 5 mg daily) compared to placebo over 12 weeks of treatment in patients with Type 2 diabetes and insufficient glycemic control. In addition, there will be an open-label treatment arm with metformin for sensitivity measurement with this patient population. Population pharmacokinetics of BI 1356 BS will also be assessed in this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
302 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo tablets matching BI 1356
Arm Title
BI 1356 0.5 mg
Arm Type
Experimental
Arm Description
BI 1356 dose 1 once daily
Arm Title
BI 1356 2.5 mg
Arm Type
Experimental
Arm Description
BI 1356 dose 2 once daily
Arm Title
BI 1356 5.0 mg
Arm Type
Experimental
Arm Description
BI 1356 dose 3 once daily
Arm Title
Metformin
Arm Type
Active Comparator
Arm Description
Metformin
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo matching BI 1356
Intervention Type
Drug
Intervention Name(s)
BI 1356 dose 3 once daily
Intervention Description
BI 1356 dose 3 once daily
Intervention Type
Drug
Intervention Name(s)
BI 1356 dose 2 once daily
Intervention Description
BI 1356 dose 2 once daily
Intervention Type
Drug
Intervention Name(s)
BI 1356 dose 1 once daily
Intervention Description
BI 1356 dose 1 once daily
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
Metformin
Primary Outcome Measure Information:
Title
Change From Baseline in HbA1c (Glycosylated Haemoglobin) at Week 12
Description
The change from baseline reflects the Week 12 HbA1c minus the Week 0 HbA1c. Means are adjusted for baseline HbA1c.
Time Frame
Baseline, week 12
Secondary Outcome Measure Information:
Title
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12
Description
Change from baseline reflects the Week 12 FPG minus the Week 0 FPG. Means are adjusted for baseline FPG.
Time Frame
Baseline, week 12
Title
Percentage of Patients With Absolute Efficacy Response (HbA1c <= 7.0%) at 12 Weeks
Description
An absolute efficacy response is defined as HbA1c <= 7.0% at 12 weeks. A non-response is defined as HbA1c > 7.0% at 12 weeks.
Time Frame
Baseline, week 12

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Male and female patients with a diagnosis of Type 2 diabetes treated only with diet and exercise (drug naïve) or with one or two oral hypoglycemic agents (as single treatment or in combination) other than rosiglitazone or pioglitazone -treatment. Antidiabetic therapy has to be stable for at least 10 weeks prior to screening. Diagnosis of Type 2 diabetes with duration of at least 3 months Glycosylated haemoglobin A1 (HbA1c) of: 7.5-10.0% at screening for drug naïve patients (no wash-out needed) 7.0-9.0% at screening for patients treated with only one oral antidiabetic agent (wash-out required) 6.5-8.0% at screening for patients treated with two oral antidiabetic agents (wash-out required) HbA1c of 7.5%-10.0% at Visit 3 (beginning of the 2-week placebo run-in period). Age >=21 and <=75 years. BMI (Body Mass Index) >=25.0 and <=40 kg/m2. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation Exclusion criteria: Clinically relevant cardiovascular disease (e.g., myocardial infarction, stroke or transient ischemic attack within six months before enrollment) Impaired hepatic function defined by serum levels of either alanine aminotransferase, aspartate aminotransferase or alkaline phosphatase above 3-fold upper limit of normal Renal insufficiency or impaired renal function defined by serum creatinine above upper limit of normal at screening Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or clinically relevant neurologic disorders (including cerebrovascular but with the exception of polyneuropathy) that would interfere with participation in the trial Chronic or clinically relevant acute infections (e.g., Human immunodeficiency virus, Hepatitis) History of relevant allergy/hypersensitivity that would interfere with trial participation (including allergy to investigational product or its excipients) Treatment with rosiglitazone or pioglitazone within 6 months prior to screening Treatment with insulin within 3 months prior to screening Alcohol or drug abuse within the last 3 months that would interfere with trial participation) Participation in another trial with an investigational drug within two months prior to administration or during the trial Fasting plasma glucose >240 mg/dl (= 13.3 mmol/L) at Visit 2, 3 or 4 any visit and confirmed by a second measurement (not on the same day) Pre-menopausal women (last menstruation <=1 year prior to signing informed consent) who: are not surgically sterile, or are nursing or pregnant; or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra-uterine devices, oral, implantable or injectable contraceptives and vasectomised partner. No exception will be made. Intolerance of metformin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Boehringer Ingelheim
Organizational Affiliation
Boehringer Ingelheim
Official's Role
Study Chair
Facility Information:
Facility Name
1218.5.10020 Boehringer Ingelheim Investigational Site
City
Chula Vista
State/Province
California
Country
United States
Facility Name
1218.5.10001 Boehringer Ingelheim Investigational Site
City
La Jolla
State/Province
California
Country
United States
Facility Name
1218.5.10007 Boehringer Ingelheim Investigational Site
City
Walnut Creek
State/Province
California
Country
United States
Facility Name
1218.5.10041 Boehringer Ingelheim Investigational Site
City
Denver
State/Province
Colorado
Country
United States
Facility Name
1218.5.10018 Boehringer Ingelheim Investigational Site
City
Hollywood
State/Province
Florida
Country
United States
Facility Name
1218.5.10016 Boehringer Ingelheim Investigational Site
City
Jacksonville
State/Province
Florida
Country
United States
Facility Name
1218.5.10003 Boehringer Ingelheim Investigational Site
City
Miami
State/Province
Florida
Country
United States
Facility Name
1218.5.10011 Boehringer Ingelheim Investigational Site
City
Miami
State/Province
Florida
Country
United States
Facility Name
1218.5.10012 Boehringer Ingelheim Investigational Site
City
Orlando
State/Province
Florida
Country
United States
Facility Name
1218.5.10017 Boehringer Ingelheim Investigational Site
City
Indianapolis
State/Province
Indiana
Country
United States
Facility Name
1218.5.10008 Boehringer Ingelheim Investigational Site
City
Topeka
State/Province
Kansas
Country
United States
Facility Name
1218.5.10024 Boehringer Ingelheim Investigational Site
City
Wichita
State/Province
Kansas
Country
United States
Facility Name
1218.5.10039 Boehringer Ingelheim Investigational Site
City
Baltimore
State/Province
Maryland
Country
United States
Facility Name
1218.5.10032 Boehringer Ingelheim Investigational Site
City
Springfield
State/Province
Massachusetts
Country
United States
Facility Name
1218.5.10025 Boehringer Ingelheim Investigational Site
City
Chesterfield
State/Province
Missouri
Country
United States
Facility Name
1218.5.10034 Boehringer Ingelheim Investigational Site
City
Butte
State/Province
Montana
Country
United States
Facility Name
1218.5.10009 Boehringer Ingelheim Investigational Site
City
Omaha
State/Province
Nebraska
Country
United States
Facility Name
1218.5.10042 Boehringer Ingelheim Investigational Site
City
Albany
State/Province
New York
Country
United States
Facility Name
1218.5.10029 Boehringer Ingelheim Investigational Site
City
Endwell
State/Province
New York
Country
United States
Facility Name
1218.5.10004 Boehringer Ingelheim Investigational Site
City
New Hyde Park
State/Province
New York
Country
United States
Facility Name
1218.5.10026 Boehringer Ingelheim Investigational Site
City
Columbus
State/Province
Ohio
Country
United States
Facility Name
1218.5.10035 Boehringer Ingelheim Investigational Site
City
Mentor
State/Province
Ohio
Country
United States
Facility Name
1218.5.10023 Boehringer Ingelheim Investigational Site
City
Medford
State/Province
Oregon
Country
United States
Facility Name
1218.5.10030 Boehringer Ingelheim Investigational Site
City
Philadelphia
State/Province
Pennsylvania
Country
United States
Facility Name
1218.5.10044 Boehringer Ingelheim Investigational Site
City
Columbia
State/Province
South Carolina
Country
United States
Facility Name
1218.5.10033 Boehringer Ingelheim Investigational Site
City
Greer
State/Province
South Carolina
Country
United States
Facility Name
1218.5.10038 Boehringer Ingelheim Investigational Site
City
Simpsonville
State/Province
South Carolina
Country
United States
Facility Name
1218.5.10006 Boehringer Ingelheim Investigational Site
City
Dallas
State/Province
Texas
Country
United States
Facility Name
1218.5.10040 Boehringer Ingelheim Investigational Site
City
Houston
State/Province
Texas
Country
United States
Facility Name
1218.5.10036 Boehringer Ingelheim Investigational Site
City
San Antonio
State/Province
Texas
Country
United States
Facility Name
1218.5.10021 Boehringer Ingelheim Investigational Site
City
Tyler
State/Province
Texas
Country
United States
Facility Name
1218.5.10027 Boehringer Ingelheim Investigational Site
City
Salem
State/Province
Virginia
Country
United States
Facility Name
1218.5.10022 Boehringer Ingelheim Investigational Site
City
Federal Way
State/Province
Washington
Country
United States
Facility Name
1218.5.10014 Boehringer Ingelheim Investigational Site
City
Renton
State/Province
Washington
Country
United States
Facility Name
1218.5.61001 Boehringer Ingelheim Investigational Site
City
Miranda
State/Province
New South Wales
Country
Australia
Facility Name
1218.5.61005 Boehringer Ingelheim Investigational Site
City
Box Hill
State/Province
Victoria
Country
Australia
Facility Name
1218.5.61006 Boehringer Ingelheim Investigational Site
City
Dandenong
State/Province
Victoria
Country
Australia
Facility Name
1218.5.61007 Boehringer Ingelheim Investigational Site
City
East Ringwood
State/Province
Victoria
Country
Australia
Facility Name
1218.5.61004 Boehringer Ingelheim Investigational Site
City
Fremantle
State/Province
Western Australia
Country
Australia
Facility Name
1218.5.61002 Boehringer Ingelheim Investigational Site
City
Nedlands
State/Province
Western Australia
Country
Australia
Facility Name
1218.5.11011 Boehringer Ingelheim Investigational Site
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
1218.5.11016 Boehringer Ingelheim Investigational Site
City
Calgary
State/Province
Alberta
Country
Canada
Facility Name
1218.5.11003 Boehringer Ingelheim Investigational Site
City
Red Deer
State/Province
Alberta
Country
Canada
Facility Name
1218.5.11004 Boehringer Ingelheim Investigational Site
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
1218.5.11013 Boehringer Ingelheim Investigational Site
City
Vancouver
State/Province
British Columbia
Country
Canada
Facility Name
1218.5.11015 Boehringer Ingelheim Investigational Site
City
Winnipeg
State/Province
Manitoba
Country
Canada
Facility Name
1218.5.11005 Boehringer Ingelheim Investigational Site
City
Hamilton
State/Province
Ontario
Country
Canada
Facility Name
1218.5.11014 Boehringer Ingelheim Investigational Site
City
Oakville
State/Province
Ontario
Country
Canada
Facility Name
1218.5.11010 Boehringer Ingelheim Investigational Site
City
Ottawa
State/Province
Ontario
Country
Canada
Facility Name
1218.5.11009 Boehringer Ingelheim Investigational Site
City
Sarnia
State/Province
Ontario
Country
Canada
Facility Name
1218.5.11012 Boehringer Ingelheim Investigational Site
City
Thornhill
State/Province
Ontario
Country
Canada
Facility Name
1218.5.11002 Boehringer Ingelheim Investigational Site
City
Toronto
State/Province
Ontario
Country
Canada
Facility Name
1218.5.11006 Boehringer Ingelheim Investigational Site
City
Montague
State/Province
Prince Edward Island
Country
Canada
Facility Name
1218.5.11017 Boehringer Ingelheim Investigational Site
City
Sainte-Foy
State/Province
Quebec
Country
Canada
Facility Name
1218.5.11018 Boehringer Ingelheim Investigational Site
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
Facility Name
1218.5.42002 Boehringer Ingelheim Investigational Site
City
Olomouc 9
Country
Czech Republic
Facility Name
1218.5.42003 Boehringer Ingelheim Investigational Site
City
Praha 4
Country
Czech Republic
Facility Name
1218.5.42005 Boehringer Ingelheim Investigational Site
City
Praha 4
Country
Czech Republic
Facility Name
1218.5.42004 Boehringer Ingelheim Investigational Site
City
Praha 9
Country
Czech Republic
Facility Name
1218.5.42001 Boehringer Ingelheim Investigational Site
City
Sternberk
Country
Czech Republic
Facility Name
1218.5.70001 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1218.5.70002 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1218.5.70003 Boehringer Ingelheim Investigational Site
City
Moscow
Country
Russian Federation
Facility Name
1218.5.70004 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1218.5.70005 Boehringer Ingelheim Investigational Site
City
St. Petersburg
Country
Russian Federation
Facility Name
1218.5.38005 Boehringer Ingelheim Investigational Site
City
Kharkov
Country
Ukraine
Facility Name
1218.5.38001 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1218.5.38002 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1218.5.38003 Boehringer Ingelheim Investigational Site
City
Kiev
Country
Ukraine
Facility Name
1218.5.38004 Boehringer Ingelheim Investigational Site
City
Lvov
Country
Ukraine
Facility Name
1218.5.38006 Boehringer Ingelheim Investigational Site
City
Vinnitsa
Country
Ukraine

12. IPD Sharing Statement

Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.5_U08-3761.pdf
Description
Related Info

Learn more about this trial

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

We'll reach out to this number within 24 hrs